Oncolytics Biotech (ONCY)

Executive Summary

Oncolytics Biotech is a clinical-stage biotechnology company developing pelareorep, a systemically delivered oncolytic virus immunotherapy designed to selectively infect and lyse cancer cells while stimulating a durable anti-tumor immune response. The company's current strategic focus is on high-need gastrointestinal cancers, including RAS-mutated metastatic colorectal cancer (mCRC) and pancreatic cancer. In April 2026, Oncolytics initiated a Phase 2 trial (NCT07446322) combining pelareorep with bevacizumab and FOLFIRI in RAS-mutated mCRC, a patient population with limited treatment options. Additionally, a Phase 1/2 study (NCT07280377) is evaluating pelareorep in combination with atezolizumab and chemotherapy in advanced anal and pancreatic cancers. The company also has prior clinical experience in multiple indications, including a completed Phase 3 in head and neck cancer. With a market capitalization of approximately $104 million, Oncolytics represents an early-stage opportunity in the oncolytic virus space, which has shown promise in turning immunologically 'cold' tumors 'hot.' However, the company's long development history and lack of approved products underscore the high-risk nature of the investment.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout for pelareorep in RAS-mutated mCRC45% success
• H2 2026Initial safety and efficacy data from Phase 1/2 trial in pancreatic and anal cancers40% success
• Q1 2027Potential partnership or licensing deal for pelareorep in GI cancers30% success